Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compe
Go back to Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compe| (NASDAQ: MDGL) | Delayed: 534.16 -6.92 (1.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $541.08 | 52 Week High | $18.24 | |||
| Open | $534.17 | 52 Week Low | $6.60 | |||
| Day High | $540.00 | P/E | N/A | |||
| Day Low | $526.67 | EPS | $0.00 | |||
| Volume | 199,463 | |||||
